20
KIT
The shape of pumps to come
A little look at what's in development in the pump
delivery arena. By Sue Marshall
The following pumps are in
development, other than two
that are already available but
not yet in the UK. For those
in development, who knows when
or if they will come to market, but
to an extent it's interesting just to
see what's underway. I've listed them
alphabetically by manufacturer name,
then product name. At this time,
there is more info on some products
than others.
Beta Bionics
iLet Bionic Pancreas
The FDA has cleared the Beta Bionics
iLet ACE Pump and the iLet Dosing
Decision Software for individuals
aged six years and older with
Type 1 diabetes.
When combined with a
compatible FDA-cleared integrated
continuous glucose monitor
(iCGM), the iLet ACE Pump and
the iLet Dosing Decision Software
form a new automated insulin
dosing (AID) system called the iLet
Bionic Pancreas.
The iLet Bionic Pancreas uses
an adaptive closed-loop algorithm
requiring only a user's body weight
for start-up and no additional insulin
dosing parameters. This adaptive
algorithm is able to determine and
command insulin delivery removing
the need to manually adjust insulin
pump therapy settings and variables.
The device also includes a new meal
announcement feature that allows
users to estimate the amount of
carbs in their meal as small, medium,
or large. The adaptive algorithm will
learn over time to respond to the
users' individual insulin needs.
Based on input from the iCGM
and meal announcements, the device
is able to independently determine
and command all basal insulin dose
adjustments, along with meal doses
of insulin.
Ed Damiano, the company's
founder and executive chair and
ever since his son developed Type 1
diabetes at 11 months of age, he has
been committed to building a bihormonal 'bionic pancreas'.
Damiano
has been a Professor of Biomedical
Engineering at America's Boston
University since 2004.
www.betabionics.com
Modular Medical
MODD1
American company Modular
Medical states that it is dedicated
to developing diabetes technology
that everyone can use and that its
goal is to liberate and empower the
entire diabetes community, fostering
better health outcomes. According
to their website, 'traditional pumps
can be overwhelming, causing
unnecessary hurdles for those
with diabetes to reclaim their lives.
MODD1 emerged from a vision to
transform this narrative, placing
everyday individuals at the heart of
our mission. Our goal is to simplify
diabetes management, ensuring that
everyone has access to the superior
care that insulin pumps offer.
With MODD1, we aim to inspire a
community where managing diabetes
is not a challenge but a journey
towards a healthier, more vibrant life.'
MODD1 has been specifically
designed for simple insulin delivery,
replacing manual injections.
Administering a bolus is simple and
discreet, allowing for on-the-go
convenience in any environment.
The MODD1 System will be
available through three convenient